AlphaQuest LLC Purchases New Position in Elevance Health, Inc. $ELV

AlphaQuest LLC acquired a new stake in Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 5,583 shares of the company’s stock, valued at approximately $1,804,000.

Several other institutional investors have also added to or reduced their stakes in ELV. Ritter Daniher Financial Advisory LLC DE raised its stake in shares of Elevance Health by 247.1% in the third quarter. Ritter Daniher Financial Advisory LLC DE now owns 3,200 shares of the company’s stock worth $1,034,000 after purchasing an additional 2,278 shares during the last quarter. Benedict Financial Advisors Inc. boosted its position in shares of Elevance Health by 4.6% during the third quarter. Benedict Financial Advisors Inc. now owns 8,749 shares of the company’s stock valued at $2,827,000 after buying an additional 384 shares during the last quarter. LRI Investments LLC increased its holdings in Elevance Health by 4.9% in the 3rd quarter. LRI Investments LLC now owns 1,686 shares of the company’s stock worth $545,000 after buying an additional 79 shares in the last quarter. Financial Security Advisor Inc. raised its position in Elevance Health by 2.0% in the 3rd quarter. Financial Security Advisor Inc. now owns 2,270 shares of the company’s stock worth $734,000 after buying an additional 44 shares during the last quarter. Finally, Activest Wealth Management lifted its stake in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ELV. Mizuho set a $413.00 price target on shares of Elevance Health in a research note on Friday, January 9th. Jefferies Financial Group cut their target price on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a research report on Friday. Truist Financial set a $400.00 target price on shares of Elevance Health in a research note on Tuesday, October 14th. Morgan Stanley dropped their price target on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. Finally, Wall Street Zen raised Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday. Thirteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $396.90.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Trading Down 0.4%

Shares of ELV stock opened at $345.62 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The company has a market cap of $76.81 billion, a price-to-earnings ratio of 13.76, a PEG ratio of 1.88 and a beta of 0.51. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75. The firm has a fifty day moving average price of $351.69 and a 200-day moving average price of $328.98.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s dividend payout ratio is presently 27.23%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.